Stimulating effect of diacerein on TGF-β1 and β2 expression in articular chondrocytes cultured with and without interleukin-1

Félisaz, Nathalie; Boumediene, Karim; Ghayor, Chafik; Herrouin, Jean-François; Bogdanowicz, Patrick; Galerra, Philippe; Pujol, Jean-Pierre

doi:10.1053/joca.1998.0199

Cited by 67 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the post-membrane level, diacerein inhibits the release of inflammatory and cartilage-degrading factors, inhibiting the activation of nuclear factor-kappa B [18]. It stimulates the production of cartilage growth factors such as transforming growth factor-beta and cartilage components, even in the presence of IL-1b [19]. This may explain the cartilage protective effects of diacerein observed in animal models of OA [20].…”

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Efficacy and Safety of Diacerein Versus S-Adenosyl Methionine in the Management of Osteoarthritis of Knee Joint

Gayathri

Samuel

Felix

et al. 2017

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Objective: Osteoarthritis (OA) the most common type of arthritis is a degenerative joint disease primarily affecting the articular cartilage and its surrounding tissue. Drugs like Diacerein and S-adenosyl methionine (SAMe) are used to remodel the cartilage and slow the progression of the disease, by acting through different mechanisms. Though there is documented evidence of the efficacy of both agents used individually in several clinical trials only a few studies report a comparison. To analyse the efficacy and safety of Diacerein Versus S-adenosyl methionine in the treatment of Osteoarthritis of the knee joint.Methods: A prospective randomised interventional study was planned comparing diacerein with SAMe for 12 w in the management of OA of the knee. 40 patients in each group were randomly assigned to receive either diacerein 50 mg twice daily or S-adenosyl methionine 200 mg thrice daily for 12 w. Both groups received a short course of diclofenac 50 mg bd for one week, to tide over the acute symptoms.Results: Assessment of both drugs individually showed an equieffective potential in reducing osteoarthritis pain over a period of 12 w. But the comparison between the two groups showed a marginal improvement in pain relief from the 4 th to 12 th week of assessment in the diacerein group. Conclusion:Both the drugs for the treatment of OA, were shown to be effective in relieving pain but with a slower onset of action. Since no radiological changes were observed during the 12-week protocol, studies of longer duration are needed to evaluate the long-term effectiveness of these drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Efficacy and Safety of Diacerein Versus S-Adenosyl Methionine in the Management of Osteoarthritis of Knee Joint

Gayathri

Samuel

Felix

et al. 2017

Int J Curr Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Rhein, the active metabolite of diacerein, has shown in vitro and in vivo the inhibition of the IL-1β, as well as the reduction of the collagenase production by joint chondrocytes, the reduction of fibrinolytic activity in synovial fluid [8,9] and the stimulation of the production of cartilage growth factors [10]. This way of action turned diacerein into an interesting option for the treatment of OA without the side effects of NSAIDs [11].…”

Section: Introductionmentioning

confidence: 99%

Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model

Permuy

López

Miño

et al. 2012

Bone

View full text Add to dashboard Cite

Background: Osteoarthritis is thought to be the most prevalent chronic and disabling joint disease in animals and humans. At present, there is no ideal treatment option. The aim of this study was to assess the effects of the treatment with oral diacerein on articular cartilage, synovial membrane and subchondral bone in an experimental rabbit model of osteoarthritis by micro-CT evaluation and histological analysis. To this purpose, osteoarthritis was surgically induced on one knee of 16 rabbits using the contralateral knee as healthy controls. Treatment was started three weeks later and lasted eight weeks. Animals were divided into two groups for treatment: Placebo (treated daily with oral saline) and diacerein (treated orally with 1.5 mg/kg/day of diacerein).

show abstract

“…In vitro studies on lapine chondrocytes have shown that diacerein can inhibit collagenase production and modulate IL-1 inhibition of proteoglycan (PG) synthesis [6]. In addition, diacerein has been implicated in the regulation of transforming growth factor (TGF) β1 and β2 in articular chondrocytes [7]. To our knowledge, no clinical study has focused on fundamental aspects; at variance, findings in different models of OA were reported recently.…”

Section: Introductionmentioning

confidence: 99%

Diacerein as a disease-modulating agent in osteoarthritis

Falgarone

Dougados

2001

Curr Rheumatol Rep

View full text Add to dashboard Cite

This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover, after an empirical use, studies return to the experimental field to understand the mechanism of action of this molecule. However, clinical trials using new sets of criteria could be conducted to estimate the structural modulating effect of diacerein; experimental studies must be performed to understand this effect.

show abstract

Stimulating effect of diacerein on TGF-β1 and β2 expression in articular chondrocytes cultured with and without interleukin-1

Cited by 67 publications

References 29 publications

Comparative Analysis of Efficacy and Safety of Diacerein Versus S-Adenosyl Methionine in the Management of Osteoarthritis of Knee Joint

Comparative Analysis of Efficacy and Safety of Diacerein Versus S-Adenosyl Methionine in the Management of Osteoarthritis of Knee Joint

Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model

Diacerein as a disease-modulating agent in osteoarthritis

Contact Info

Product

Resources

About